Business Context and Reporting Period
This Form 6-K filing by Midatech Pharma PLC (now Biodexa Pharmaceuticals Plc) covers the month of March 2023, specifically reporting on the results of a General Meeting held on March 24, 2023. The Company is a foreign private issuer transitioning its corporate structure and trading venues.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and capital structure changes.
Material Changes
- Corporate Name Change: The Company's name was changed from Midatech Pharma PLC to Biodexa Pharmaceuticals Plc, effective on or about March 27, 2023.
- Reverse Stock Split: A 1-for-20 reverse stock split of Ordinary Shares was authorized, effective on or about March 27, 2023.
- ADS Ratio Adjustment: The American Depositary Share (ADS) ratio will change from 25 Ordinary Shares per ADS to 5 Ordinary Shares per ADS, effectively a 1-for-4 reverse split of ADSs.
- Delisting from AIM: The Company's Ordinary Shares will be cancelled from admission on the London Stock Exchange's AIM market, effective on or about April 26, 2023.
- Trading Venue: Following the AIM delisting, ADSs will continue to trade on the NASDAQ Capital Market.
- Share Issuance Authority: Shareholders approved the allotment of up to 100% of fully diluted share capital for future issuances through the 2025 annual general meeting.
- Warrant Exercise: Shareholders approved the disapplication of preemption rights for shares issued upon the exercise of Series A, Series B, and pre-funded warrants from a private placement closed on February 15, 2023.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on operational outlook, or specific risk factors beyond the structural changes noted. The primary contingency is the successful implementation of the reverse stock split and the transition of trading from AIM to NASDAQ.
Investor Verification Checklist
- Confirm the effective date of the name change to Biodexa Pharmaceuticals Plc (expected March 27, 2023).
- Verify the implementation of the 1-for-20 reverse stock split and the corresponding 1-for-4 ADS adjustment.
- Monitor the delisting of Ordinary Shares from AIM (expected April 26, 2023) and the continued listing of ADSs on NASDAQ.
- Review the terms of the private placement warrants (Series A, Series B, and pre-funded) approved for exercise without preemption rights.
- Check for subsequent filings regarding the 100% share issuance authority granted for the period through 2025.